Double-Blind Study Using Eye Tracking to Predict Naltrexone Response in Adults With Gaming Disorder

What this Trial Is About

Researchers are conducting a double-blind controlled study to explore whether the response to naltrexone can be predicted in individuals diagnosed with videogame disorder, a form of behavioral dependence on video games. The study focuses on a specific subgroup of videogame disorder characterized by symptoms such as salience, withdrawal, relapse, conflict, mood modification, and craving. This Phase 2 trial aims to better understand treatment response using eye-tracking technology to analyze attentional bias over a 12-week period. Participants will receive naltrexone or placebo in a crossover design over 12 weeks with flexible dosing. The study includes 4 sessions of psychoeducational intervention and 4 eye-tracking assessments to monitor attentional patterns. The naltrexone or placebo is administered orally once daily with scheduled switches between drug and placebo during the trial and regular eye-tracking evaluations before and after dosing. Psychoeducational sessions occur at weeks 2, 4, 6, and 8. Throughout the study, participants undergo multiple assessments including clinical interviews, standardized questionnaires for gaming disorder severity, impulsivity, social adjustment, anxiety, depression, and side effects. Eye-tracking data are collected at four key points to evaluate attentional bias. Researchers will measure outcomes such as changes in gaming disorder symptoms and craving using validated scales. The trial includes safety monitoring and lasts up to 12 weeks for each participant, with ongoing data collection and follow-up.

Predicting Response to Naltrexone With Eye Tracking in Gaming Disorder